Enzyme test may predict chemo success in breast cancer
NCT ID NCT04198727
First seen Jun 05, 2026 · Last updated Jun 13, 2026 · Updated 4 times
Summary
This study checks if a person's natural DPD enzyme activity influences how well the chemotherapy drug capecitabine works for metastatic breast cancer. About 155 women with HER2-negative breast cancer will have their DPD levels measured before starting treatment. Researchers will then track tumor response and side effects for up to 24 months to see if DPD activity predicts outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Azuréen de Cancérologie
Mougins, 06250, France
-
Clinique Saint Jean
Cagnes-sur-Mer, 06800, France
-
Clinique St Georges
Nice, 06105, France
-
Hôpital Princesse Grâce
Monaco, 98000, Monaco
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.